Clinical Trial Update: DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients

View source ↗

Summary

DiviTum TKa is being evaluated as a biomarker assay in a clinical trial for efficacy in HR-positive, HER2-negative metastatic breast cancer; the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• DiviTum TKa

Snippet

Sponsor: Mayo Clinic | Conditions: HER2-negative Breast Cancer, Hormone-receptor-positive Breast Cancer | Status: RECRUITING